PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1997/50/3.


Jan Kulpa 1, Ewa Wójcik 1, Jan Latała 2, Zygmunt Dobrowolski 3, Andrzej Stelmach 1
Zakład Analityki i Biochemii Klinicznej Centrum Onkologii, Oddział w Krakowie
Dyrektor Centrum: prof. dr hab. med. Jan Skołyszewski
Kierownik Zakładu: dr n. chem. Jan Kulpa
1 Klinika Chirurgii Onkologicznej, Centrum Onkologii, Oddział w Krakowie
Kierownik Kliniki: doc. dr hab. med. Leszek Kołodziejski
2 Oddział Urologii, Woj. Szpital Zespol, im. G. Narutowicza w Krakowie
Ordynator Oddziału: dr med. Marek Gałka
3 Klinika Urologii Collegium Medicum UJ w Krakowie
p. o. Kierownik Kliniki: doc. dr hab. med. Zygmunt Dobrowolski


prostate prostatic cancer orchidectomy PSA, PAP hormonal status


Material and methods. The serum concentration of PSA, PAP, total
testosterone, SHBG, albumin, LH, FSH and prolactin were determined in 20
patients with prostate cancer before and 7 days after orchidectomy. Free
testosterone level in serum was calculated for each patients basing on total
testosterone, SHBG, and albumin concentrations.
Results. Seven days after surgical castration when, compare to preoperative
values, significant decrease of free testosterone (p<0.0001), PSA (p<0.001) and
albumin (p<0.003) concentrations were found, while LH and FSH levels
p<0.008 and p<0.0004 respctively
of SHBG, prolactin, and PAP didn't demonstrate significant changes compared
to preoperative level. At 7th day after operation significant positive correlation
in prolactin vs. free testosterone level (p<0.002) and prolactin vs. PSA
concentration (p<0.01) were observed. It might point to on important role of
testosterone, produced in the periphery from adrenal substrates in controling
cellular growth and function of prostate gland after castration.
Conclusions. The observed decrease of PSA concentrations reflected changes
in hormonal status. The results of PAP level may be a more adequate index of
neoplastic process at that period of time.


  1. [1] Adlercreutz, H., Ranniko, S., Kairento, A. L., Karonen, S. L.: Hormonal
  2. pattern in prostatic cancer. II. Correlation with primary response to endocrine
  3. treatment. Acta Endocrinol., 1981, 98, 634-640.
  4. [2] Bartsch, W., Horst, H. ]., Becker, H., Nehse, G.: Sex hormone binding
  5. globulin binding capacity, testosterone, 5 alpha-dihydrotestosterone, oestradiol and
  6. prolactin in plasma of patients with prostatic carcinoma under yarious types of
  7. hormonal treatment. Acta Endocrinol., 1977, 85, 650-664.
  8. [3] Bruchovsky, N., Lesser, B., van Doorm, E., Craven, S.: Hormonal effects
  9. on cell proliferation in rat prostate. Vitamin Horm., 1975, 33, 61-102.
  10. [4] Csapo, Z., Brand K., Walther, R., Fokas K.: Comparative experimental stu-
  11. dy of the serum prostate specific antigen and prostatic acid phosphatase in serially
  12. transplantable human prostatic carcinoma lines in nude mice. J. Urol., 1988,140,
  13. 1032-1038.
  14. [5] Davies, P., Eaton, C. L.: Regulation of prostate growth. J. Endocrinol., 1991,
  15. 131, 5-17.
  16. [6] Denis, L.: Prostate cancer. Primary hormonal treatment. Cancer, 1993, 71,1050-
  17. 1058.
  18. [7] Geller, 1.: Basis for hormonal management of advanced prostate cancer. Cancer,
  19. 1993, 71, 1039-1045.
  20. [8] Geller, }., Liu, ]., Albert, }., Fay, W., Berry, C. C, Weis, P.: Relationship
  21. between human prostatic epithelial cell synthesis and tissue dihydrotestosterone
  22. level. Clin. Endocrinol., 1987, 26, 155-161.
  23. [9] Ghanadian, R., Puah, C. M., O'Donoghue, E. P. N.: Serum testosterone
  24. and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 1979, 39,
  25. 696-699.
  26. [10] Grasso, M., Buonaquidi, A., Mondina, R., Borsellino, G., Lania C,
  27. Banfi, G., Rigatti, P.: Plasma sex hormone binding glubulin in patients with
  28. prostatic carcinoma. Cancer, 1990, 66, 354-357.
  29. [11] Habib, K. A., Lee, I. R., Stitch, S. R., Smith, P. H.: Androgen levels in the
  30. plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of
  31. the prostate. J. Endocrinol., 1976, 71, 99-107.
  32. [12] Hanash, K. A., Mostofi, K. F.: Androgen effect on prostate specific antigen
  33. secretion. J. Surg. Oncol., 1992, 49, 202-204.
  34. [13] Henttu, P., Liao, S., Vihko, P.: Androgens up-regulate the human Prostate-
  35. specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prosta-
  36. tic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 1992, 130,
  37. 766-772.
  38. [14] Levell, M. J., Rowe, E., Glasham, R. W., Pidcock, N. B., Siddall, J. K.:
  39. Free testosterone in carcinoma of the prostate. The Prostate, 1985, 7, 363-367.
  40. [15] Levell, M. }., Siddall, J. K., Rowe, E., Glasham, R. W., Robinson, M. R. G.,
  41. Pidcock, N. B.: Relationship of testosterone, sex hormone binding globulin, and
  42. calculated free testosterone to subse±uent clinical progress in patients with carci-
  43. noma of the treated with bilateral orchdectomy or estrogens. The Prostate, 1987,
  44. 1, 17-21.
  45. [16] Marczyńska, A., Kulpa, }., Wójcik, E., Leńko, ]., Bugajski, A.: Prostate
  46. cancer - serum testosterone, sex hormone binding globulins (SHBG) and testoste-
  47. rone free index (TFI). Archiv Urol., 1990, 31, 57-66.
  48. [17] McConnell, J. D.: Androgen ablation and blockade in the treatment of benign
  49. prostatic hyperplasia. Urol. Clin. North Am., 1990, 17, 661-670.
  50. [18] Oesterling, J. E., Andrews, P. E., Suman, V. }., Zincke, H., Myeres, R. P:
  51. Preoperative androgen deprwation therapy: Artificial lowering of serum prostate
  52. antigen without downstaging the tumor. J. Urol., 1993, 149, 779-782.
  53. [19] Rohl, H. F., Benke, H. P: Effect of orchidectomy on serum concentrations of
  54. testosterone and dihydrotestosterone in patients with prostatic cancer.
  55. Scand. J. Urol. Nephrol., 1992, 26, 11-14.
  56. [20] Weber, J. P, Oesterling, J. E., Peters, C. A., Partin, A. W., Chan, D. W.,
  57. Walsh, P. C: The influence of reversible androgen deprwation on serum prostate
  58. antigen levels in men with benign prostatic hyperplasia. J. Urol., 1989,141, 987-
  59. 992.